To further determine the prevalence of the PLEKHA1-TACC2 fusion in ESCC, we examined 404 tumor samples from ESCC patients using RT-PCR as described above and found the existence of PLEKHA1-TACC2 in 66 ESCC samples (16.3%) (Fig. 1D). Here, TACC2 is linked to neoplasm.